- $743.48m
- $694.28m
- $233.26m
- 59
- 37
- 66
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 33.9 | 78.7 | 223 | 237 | 233 |
Cost of Revenue | |||||
Gross Profit | 17.4 | 36.3 | 96.6 | 104 | 99.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 51.6 | 109 | 492 | 269 | 343 |
Operating Profit | -17.7 | -30 | -270 | -31.9 | -109 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.3 | -32.7 | -274 | -35.1 | -99.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.3 | -32.7 | -276 | -37.3 | -99.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.3 | -32.7 | -276 | -37.3 | -99.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.3 | -75 | -284 | -45.3 | -108 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.549 | -1.94 | -2.63 | -0.897 | -1.53 |